Emergency Medicine · Toxicology
The facts most likely to be tested
Press 1–5 to rate · ↑↓ to navigate
The classic triad is bradycardia, hypotension, and hyperglycemia with initially normal mental status, most often from non-dihydropyridines (verapamil, diltiazem).
Hyperglycemia is the key board clue distinguishing CCB from beta-blocker overdose (which causes hypoglycemia/euglycemia).
Cornerstone antidotes are IV calcium and high-dose insulin euglycemic therapy (HIET), which acts as an inotrope by enabling myocardial carbohydrate use.
Atropine and IV crystalloids are first stabilization steps but atropine is frequently ineffective for CCB-induced bradycardia.
ECG classically shows sinus bradycardia, junctional rhythms, or varying degrees of AV block.
HIET requires aggressive dextrose and potassium co-administration to prevent hypoglycemia and hypokalemia.
Refractory cardiovascular collapse requires norepinephrine, 20% IV lipid emulsion (ILE), or ECMO, with prolonged ICU monitoring for extended-release formulations.
Vignette unlocked
A 56-year-old woman is brought to the ED two hours after an intentional overdose of her extended-release verapamil. She is alert but appears unwell. Blood pressure is 76/44 mm Hg and pulse is 42/min. Lungs are clear. ECG shows sinus bradycardia with a prolonged PR interval, and a basic metabolic panel reveals a glucose of 268 mg/dL.
In addition to IV calcium, which of the following therapies is the most appropriate antidote?
High-dose insulin euglycemic therapy (HIET).
Bradycardia, hypotension, clear lungs, and hyperglycemia after verapamil ingestion are classic for calcium channel blocker toxicity, with hyperglycemia distinguishing it from beta-blocker overdose. HIET provides positive inotropy by promoting myocardial carbohydrate utilization and is administered alongside IV calcium, with dextrose and potassium supplementation to prevent hypoglycemia and hypokalemia.
Full handout
High yield triage
Etiology / Epidemiology
High-mortality toxidrome most frequently caused by intentional ingestions of non-dihydropyridines (verapamil, diltiazem).
Clinical Manifestations
Presents with the classic triad of bradycardia, hypotension, and hyperglycemia with normal mental status initially.
Diagnosis
Diagnosed clinically alongside an ECG showing AV blocks and a metabolic panel revealing hyperglycemia.
Treatment
Resuscitate with IV Calcium, High-dose insulin euglycemic therapy (HIET), and vasopressors for refractory shock.
Prognosis
High risk of fatal cardiovascular collapse requiring prolonged ICU monitoring due to extended-release formulations.
Full handout
Epidemiology & Etiology
CCB toxicity is a leading cause of fatal cardiovascular drug ingestions in adults. Toxicity is dose-dependent, but non-dihydropyridines (verapamil and diltiazem) are inherently more lethal due to direct myocardial depression. Dihydropyridines (amlodipine) primarily cause profound peripheral vasodilation but can induce reflex tachycardia initially before progressing to bradycardia in massive overdoses. Extended-release formulations create a severe risk for delayed-onset precipitous hemodynamic collapse.
Pertinent Anatomy
L-type voltage-gated calcium channels are localized across three critical tissues: the sinoatrial/atrioventricular nodes, the peripheral vascular smooth muscle, and the beta-islet cells of the pancreas. Blockade at the cardiac nodes impairs the pacemaker current, while peripheral blockade prevents smooth muscle contraction. Pancreatic channels are required to trigger calcium-dependent insulin exocytosis.
Pathophysiology
Toxicity occurs via overwhelming blockade of L-type calcium channels, preventing extracellular calcium influx. Decreased intracellular calcium in the myocardium causes negative inotropy, chronotropy, and dromotropy, leading to cardiogenic shock. Peripheral vascular smooth muscle relaxation causes profound vasodilation and distributive shock. Crucially, blockade of pancreatic calcium channels halts insulin secretion, forcing the myocardium to shift from utilizing free fatty acids to carbohydrates, which it cannot process without insulin, resulting in cellular energy failure and systemic hyperglycemia.
Clinical Manifestations
Patients classically present with hypotension and bradycardia, often maintaining a clear sensorium until cerebral perfusion critically drops. Lungs are characteristically clear on auscultation, contrasting with primary heart failure. Severe cases rapidly progress to profound cardiogenic shock and cardiac arrest. Look for the classic board clue of hyperglycemia in a bradycardic, hypotensive patient to differentiate it from other toxidromes.
Diagnosis
The diagnosis is primarily clinical based on the toxidrome and medication history. The gold standard for initial evaluation is a 12-lead ECG, typically demonstrating sinus bradycardia, junctional rhythms, or varying degrees of AV block. A basic metabolic panel is mandatory to identify hyperglycemia, which directly correlates with the severity of the overdose and is the key differentiator from beta-blocker toxicity.
Treatment
Initial stabilization requires IV crystalloids and Atropine, though atropine is frequently ineffective for CCB-induced bradycardia. The cornerstone antidotes are IV Calcium (calcium chloride via central line or calcium gluconate peripherally) to competitively overcome the channel blockade, and High-dose insulin euglycemic therapy (HIET). HIET acts as a powerful inotrope by facilitating myocardial carbohydrate utilization; it requires aggressive co-administration of dextrose and potassium to prevent hypoglycemia and hypokalemia. Refractory cases necessitate vasopressors like Norepinephrine or salvage therapy with 20% Intravenous Lipid Emulsion (ILE) and extracorporeal membrane oxygenation (ECMO).
Prognosis
Morbidity and mortality are driven by refractory mixed cardiogenic and distributive shock. Patients require intensive care monitoring for at least 24 hours (or much longer for extended-release preparations) due to the risk of delayed fatal arrhythmias. Close serial monitoring of blood glucose and potassium is mandatory during HIET administration.
Differential Diagnosis
1. Beta-blocker overdose: Presents identically with bradycardia and hypotension but classically features hypoglycemia or euglycemia rather than hyperglycemia.
2. Digoxin toxicity: Features bradycardia and visual disturbances (xanthopsia) with characteristic ECG findings like scooped ST segments and hyperkalemia.
3. Clonidine overdose: Presents with bradycardia and hypotension but is distinguished by central nervous system depression and pinpoint pupils (miosis).